Study to Evaluate DT-216 in Adult Patients With Friedreich Ataxia

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic effects of intravenous DT-216 in adult patients with Friedreich Ataxia. This single ascending dose study is randomized, double-blind, placebo-controlled.
Epistemonikos ID: 9cdd79c7227dbd2d9be8dc777904269bfc95a23e
First added on: May 10, 2024